Clearside Biomedical (CLSD) announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema, UME. XIPERE is approved for use in the United States, Canada, Australia, and Singapore and under regulatory review in China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Snowflake initiated, Chipotle upgraded: Wall Street’s top analyst calls
- Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright
- Clearside Biomedical downgraded to Neutral from Buy at Chardan
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties